卡泊芬净在移植患者中应用的安全性评价

 目的拟对卡泊芬净在器官移植术后患者深部真菌感染治疗过程中的安全性进行评价。方法采用病例对照研究方法,以应用氟康唑或两性霉素B治疗的患者为对照组,数据采用SPSS14.0处理。结果试验组和对照2组患者治疗前后ALT,对照2组患者治疗前后血BUN治疗前后的差异有统计学意义(P<0.05)。试验组和对照2组用药后血浆电解质水平有所变化(P<0.05)。对照1组用药前后他克莫司血药浓度有统计学意义。3组不良反应发生率分别为5.6%,5.6%和14.3%。结论卡泊芬净用于治疗移植术后患者深部真菌感染有较好的安全性。

Evaluation of Efficacy and Safety of Caspofungin in Organ Recipients

OBJECTIVE To evaluate the influence of caspofungin on physicological function, incidence of caspofungin of ADRs and to investigate the effect on the blood level of Tacrolimus, a immunosuppressant. METHODS A case-control study were administered one of caspofungin, Fluconazol or Amphotericin B. The data was analysed statistically by SPSS 14.0. RESULTS The physiological indexes between 3 groups before administration showed no significant difference. ALT level of test group and control group 2 showed significant difference between before and after administration. BUN level of before and after administration of control group 2 had statistical significance. Blood level of K⁺ in test group was increased significantly after administration. Blood level of Na⁺ in control group 2 was decreased significantly after administration. Blood level of tacrolimus in control group 1 was increased after administration. The incidence of ADRs in three groups were 5.6%,5.6%and 14.3%, respectively. CONCLUSION Caspofungin has equivalent therapeutic effect compared with fluconazol and amphotericin B. The incidence of ADRs was lower than control group 2.